Morgan Stanley (NYSE:MS) analyst Matthew Harrison maintained a Hold rating on Editas Medicine (NASDAQ:EDIT) Inc on Tuesday, setting a price target of $31, which is approximately 3.79% below the present share price of $32.22.
Harrison expects Editas Medicine Inc to post earnings per share (EPS) of -$0.43 for the fourth quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Editas Medicine, with an average price target of $45.5.
The analysts price targets range from a high of $65 to a low of $30.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $10.75 million and a net profit of -$31.34 million. The company's market cap is $2.01 billion.
According to TipRanks.com, Morgan Stanley analyst Matthew Harrison is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 17.1% and a 62.50% success rate.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.